CPA1 Antikörper (full length)

Produktnummer ABIN7877782

Der Maus Monoklonal anti-CPA1 Antikörper (Klon CPA1-2711) (ABIN7877782) detektiert spezifisch CPA1 in WB und IHC (p). Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für CPA1 Antikörper (full length) (ABIN7877782)

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CPA1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: CPA1-2711

Produktdetails anti-CPA1 Antikörper

Bindungsspezifität: full length

Verwendungszweck: CPA1 Antibody / Carboxypeptidase A1 (azide and preservative free)

Aufreinigung: Protein G affinity chromatography

Immunogen: Full length recombinant human Carboxypeptidase A1 protein was used as the immunogen for the CPA1 antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Carboxypeptidase A1 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the Carboxypeptidase A1 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Details zu CPA1

Target: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Andere Bezeichnung: CPA1

Hintergrund: Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.

UniProt: P15085